Dual-assist heterologous antigens screening: An effective strategy to improve the sensitivity of lateral flow immunoassay

Heterologous strategy has promising applications in improving the sensitivity of competitive immunoassay. In this study, the potential heterologous coating antigens (HEA) were screened from eight imidacloprid (IMI) structural analogs based on the cross-reactivity (CR) of a prepared antibody. Computer-aided molecular modeling was used to predict the optimal HEA. Compared with the homologous coating antigen (HOA), the predicted HEA prepared from acetamiprid (CR = 0.23 %) increased the detection sensitivity of the enzyme-linked immunoassay and colloidal gold nanoparticle-based lateral flow immunoassay (HOA-Au-LFIA) by 5.6 and 4.1 times, respectively. Subsequently, the HEA and aggregation-induced emission fluorescent labels were integrated into a lateral flow immunoassay platform (HEA-AIE-LFIA). The limit of detection was 0.12 ng mL